We demonstrated that activated transcytosis is Diabetes Monitoring - Lancets and Lancing Devices a major mechanism to complement the classic enhanced permeability and retention effect in pancreatic cancer.This was achieved by using an iRGD peptide that triggers transcytosis pathway at the tumor site.Co-administration of unconjugated iRGD substantially improved the effect of the chemotherapeutics delivering nanocarrier, and resulted in survival improvement in mice.
Since the iRGD effect TRUE FOCUS is commensurate with neuropilin-1 expression on tumor vasculature, it is necessary to contemplate a personalized approach to implement this technology.